|
Lipid-modifying Efficacy of Simgal in Patients
Undergoing |
G.
Chapidze, S. Kapanadze, N. Dolidze, A. Chukhrukidze
|
|
In
order to evaluate lipid-modifying efficacy of a new member from
simvastatins class – Simgal, 29 patients’ blood lipid status was
examined. 21 patients had undergone coronary artery bypass graft operation
and 8 patients – percutaneous coronary intervention. Duration of the
follow-up was 4 weeks. On the background of 10mg/daily Simgal we observed
statistically significant changes in all lipid parameters except
triglycerides (TG). Simgal lowered total cholesterol, low-density
lipoprotein cholesterol (LDL-C), TG, β and pre-β lipoproteines
and atherogenic ratio by 26%, 34%, 9%, 22% and 41%, respectively.
High-density lipoprotein cholesterol (HDL-C) was increased by 14%.
The target levels of HDL-C (>40mg/dL), LDL-C (<100mg/dL) and TG
(<150mg/dL) were obtained in 93%, 90% and 24% cases, respectively.
Lipid-lowering efficacy of Simgal was mainly expressed in relation to one
of the most important lipid risk factors and predictor of development of
new stenosis and occlusion in native coronary arteries and bypass
grafts─elevated levels of LDL-C. In achieving the NCEP lipid goals
Simgal was the most efficacious in association with antiatherogenic lipid
fraction – HDL-C. Simgal was well-tolerated and safe for patients. No
serious adverse event occurred during the study period. One patient had
myalgia of inferior limbs without creatine kinase elevation. There were no
liver enzyme increase above 2 upper limit of normal. In
conclusion, the obtained short-term results of the present study suggest
that the treatment of CHD patients undergoing myocardial revascularization
with 10mg/daily Simgal is beneficial for the correction of dyslipidemia.
Major steps should be taken to convince Georgian physicians about the
benefits of this cost-effective statin therapy in secondary CHD
prevention. IVAX Corporation has kindly provided us with Simgal. |
|
Literature: 1.
Executive summary of the third report of the National Cholesterol
Education Program (NCEP) expert panel on detection, evaluation, and
treatment of high blood cholesterol in adults (Adult Treatment Panel III).
JAMA; 2001; 285; 2486-2497. 2.
Ginsberg H.N. Hypertriglyceridemia: new insights and new approaches
to pharmacologic therapy. Am J Cardiol; 2001;87; 1174-1180. 3.
Christenson J.T. Preoperative lipid control with simvastatin
reduces the risk for
graft failure already 1 year after myocardial revascularization.
Cardiovasc Sur.; 2001;9; 33-43. 4.
Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of
atorvastatin on early recurrent ischemic events in acute coronary
syndromes. The MIRACL Study: a randomized controlled trial. JAMA;
2001;285;1711-1718. 5.
Сусеков
А.В.,
Соловьёва Е.Ю.,
Рожкова Т.А. и
др.
Симвастатин
при лечении
больных с
первичной
гиперхолестеринемией:
переносимость
и
эффективность
суточных
доз 10-80 мг.
Кардиология;
2000; №1; 33-36. 6.
Аронов Д.М.
Плеотропные
эффекты
статинов.
Русский мед.
журнал; 2001; 2-7. 7.
Clark L.T. Treating dyslipidemia with statins: the risk-benefit
profile. Am Heart J; 2003;145; 8.
Kalovou G. The treatment of coronary heart disease: statins beyond
cholesterol loworing. Curr Med Res Opin; 2001; 17; 34-7.
|